How could Glenmark's IND application for solid tumour drug affect the Center for Drug Evaluation and Research?
CDER must review Glenmark's new cancer drug application for clinical trials. The submission of the Investigational New Drug (IND) application for ISB 2301 requires the U.S. Food and Drug Administration (FDA) to initiate a regulatory review. As a division of the FDA, the Center for Drug Evaluation and Research (CDER) is responsible for evaluating this drug candidate. The review will assess the safety, tolerability, pharmacokinetics, and anti-tumour activity of ISB 2301, which is designed to target solid tumours. This review is necessary before the company can proceed with planned Phase I clinical trials in 2027.
- Effect
- Mixed
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- No new developments lately
How it reaches Center for Drug Evaluation and Research
-
Ichnos Glenmark Innovation, a joint venture between Glenmark Pharmaceuticals and Ichnos Sciences, submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on November 17, 2026, for the experimental cancer drug ISB 2301. The drug is a pentaspecific molecule designed to target solid tumors. The company plans to initiate Phase I clinical trials in 2027, pending regulatory clearance.
The full event1independent outlet -
As a formal division of the FDA, the Center for Drug Evaluation and Research (CDER) is responsible for the regulatory oversight and evaluation of drug candidates like ISB 2301. CDER must assess the preclinical data, which showed favourable pharmacokinetic and tolerability profiles in non-human primates, to determine if the drug can proceed to clinical evaluation in patients with advanced solid tumours.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
FDA research center
Everything about Center for Drug Evaluation and Research
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- IGI submitted an IND application to the US FDA for ISB 2301.business-standard.com
- ISB 2301 is a pentaspecific molecule designed to target solid tumours.business-standard.com
- The company plans to initiate a Phase I clinical trial in 2027, subject to regulatory clearance.business-standard.com
- Preclinical studies demonstrated favourable pharmacokinetic and tolerability profiles in non-human primates.business-standard.com
Why it matters
The IND submission is a critical step for IGI's oncology pipeline, expanding its development program beyond blood cancers into the challenging area of solid tumours. Successful progression through CDER's review would allow the company to move forward with Phase I trials, potentially bringing a first-in-class treatment to patients with advanced solid tumours.
CDER's role is central to the global drug development process, acting as the gatekeeper for new therapies entering human trials. The review process ensures that the drug candidate meets rigorous safety and efficacy standards before it can be tested in patients, which is a standard requirement for all new pharmaceutical submissions to the FDA.
What we don't know yet
- What specific data points will CDER focus on during the review of ISB 2301?
- What is the expected timeline for CDER to grant or deny the IND application?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
- European Medicines AgencyPossibleThe US regulatory progress may influence the EMA's review of ISB 2301.
- European CommissionPossibleUS cancer drug progress may influence European Commission's regulatory strategy
- Eli Lilly and CompanyPossibleIncreased competition in solid tumor oncology may challenge Eli Lilly's market position.
- Merck Sharp & DohmePossibleNew pentaspecific cancer drug could increase competition for Merck Sharp & Dohme
Reporting
- business-standard.comTuesday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.